Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-20-135603
Filing Date
2020-05-07
Accepted
2020-05-07 07:32:27
Documents
60
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d917013d10q.htm   iXBRL 10-Q 1426756
2 EX-31.1 d917013dex311.htm EX-31.1 6458
3 EX-31.2 d917013dex312.htm EX-31.2 6410
4 EX-32 d917013dex32.htm EX-32 4910
  Complete submission text file 0001193125-20-135603.txt   7190608

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA itci-20200331.xsd EX-101.SCH 40557
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE itci-20200331_cal.xml EX-101.CAL 35003
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE itci-20200331_def.xml EX-101.DEF 259806
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20200331_lab.xml EX-101.LAB 402738
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20200331_pre.xml EX-101.PRE 368366
15 EXTRACTED XBRL INSTANCE DOCUMENT d917013d10q_htm.xml XML 1521751
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

EIN.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36274 | Film No.: 20854581
SIC: 2834 Pharmaceutical Preparations